Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gavin A Lewis

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of the American Heart Association|July 21, 2022
Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of PirfenidoneGavin A Lewis, Anna Rosala-Hallas, Susanna Dodd, et al.
The International Journal of Cardiovascular Imaging|February 9, 2022
Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fractionGavin A Lewis, Anna Rosala-Hallas, Susanna Dodd, et al.
Journal of Cardiac Failure|March 15, 2023
Treatment Adherence in a Randomized Controlled Trial of Pirfenidone in HFpEF: Determinants and Impact on EfficacyFardad Soltani, Gavin A Lewis, Anna Rosala-Hallas, et al.
The Lancet. Digital Health|May 13, 2022
Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation studyJoshua Bradley, Erik B Schelbert, Laura J Bonnett, et al.
Heart (British Cardiac Society)|August 11, 2023
Growth differentiation factor-15 in patients with or at risk of heart failure but before first hospitalisationJoshua Bradley, Erik B Schelbert, Laura J Bonnett, et al.
Nature Medicine|August 13, 2021
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trialGavin A Lewis, Susanna Dodd, Dannii Clayton, et al.
Cardiovascular Drugs and Therapy|May 10, 2019
Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE TrialGavin A Lewis, Erik B Schelbert, Josephine H Naish, et al.
European Heart Journal|November 23, 2017
The effect of 1.5 T cardiac magnetic resonance on human circulating leucocytesWilliam R Critchley, Anna Reid, Julie Morris, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|July 25, 2024
Remote myocardial fibrosis predicts adverse outcome in patients with myocardial infarction on clinical cardiovascular magnetic resonance imagingNicholas Black, Joshua Bradley, Erik B Schelbert, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of the American Heart Association|July 21, 2022
Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of PirfenidoneGavin A Lewis, Anna Rosala-Hallas, Susanna Dodd, et al.
The International Journal of Cardiovascular Imaging|February 9, 2022
Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fractionGavin A Lewis, Anna Rosala-Hallas, Susanna Dodd, et al.
Journal of Cardiac Failure|March 15, 2023
Treatment Adherence in a Randomized Controlled Trial of Pirfenidone in HFpEF: Determinants and Impact on EfficacyFardad Soltani, Gavin A Lewis, Anna Rosala-Hallas, et al.
The Lancet. Digital Health|May 13, 2022
Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation studyJoshua Bradley, Erik B Schelbert, Laura J Bonnett, et al.
Heart (British Cardiac Society)|August 11, 2023
Growth differentiation factor-15 in patients with or at risk of heart failure but before first hospitalisationJoshua Bradley, Erik B Schelbert, Laura J Bonnett, et al.
Nature Medicine|August 13, 2021
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trialGavin A Lewis, Susanna Dodd, Dannii Clayton, et al.
Cardiovascular Drugs and Therapy|May 10, 2019
Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE TrialGavin A Lewis, Erik B Schelbert, Josephine H Naish, et al.
European Heart Journal|November 23, 2017
The effect of 1.5 T cardiac magnetic resonance on human circulating leucocytesWilliam R Critchley, Anna Reid, Julie Morris, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|July 25, 2024
Remote myocardial fibrosis predicts adverse outcome in patients with myocardial infarction on clinical cardiovascular magnetic resonance imagingNicholas Black, Joshua Bradley, Erik B Schelbert, et al.
Pageof 2